CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFκB pathway in hepatocellular carcinoma.
Apoptosis
Carcinoma, Hepatocellular
/ genetics
Cell Cycle
Cell Cycle Proteins
/ metabolism
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
Down-Regulation
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Liver Neoplasms
/ genetics
NF-kappa B
/ physiology
Neoplasm Invasiveness
Neoplasm Metastasis
Prognosis
Reactive Oxygen Species
/ metabolism
Signal Transduction
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
07 05 2020
07 05 2020
Historique:
received:
20
09
2019
accepted:
20
04
2020
revised:
18
04
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
19
3
2021
Statut:
epublish
Résumé
CR6-interacting factor 1 (Crif1) is a mitochondrial protein which is required for the assembly of oxidative phosphorylation (OXPHOS) complexes. Our bioinformatics analysis based on Cancer Genome Atlas (TCGA) database revealed an aberrant overexpression of CRIF1 in hepatocellular carcinoma (HCC). However, the clinical significance and biological functions of CRIF1 are still unclear in this malignancy. Here, we report that CRIF1 is frequently overexpressed in HCC cells mainly due to the downregulation of miR-497-5p, which is associated with poor prognosis of patients with HCC. CRIF1-promoted HCC growth and metastasis by suppressing cell apoptosis and inducing cell cycle progression and epithelial to mesenchymal transition (EMT). Mechanistically, increased mitochondrial ROS production and consequently activation of the NFκB signaling pathway was found to be involved in the promotion of growth and metastasis by CRIF1 in HCC cells. In summary, CRIF1 plays an oncogenic role in HCC progression through activating ROS/NFKB pathway, implying CRIF1 as a potential prognostic factor and therapeutic target in HCC.
Identifiants
pubmed: 32382077
doi: 10.1038/s41419-020-2528-7
pii: 10.1038/s41419-020-2528-7
pmc: PMC7205899
doi:
Substances chimiques
Cell Cycle Proteins
0
GADD45GIP1 protein, human
0
NF-kappa B
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
332Références
Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).
doi: 10.1016/j.ejca.2018.07.005
Fu, J. & Wang, H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 412, 283–288 (2018).
doi: 10.1016/j.canlet.2017.10.008
Malina, C., Larsson, C., Nielsen, J. Yeast mitochondria: an overview of mitochondrial biology and the potential of mitochondrial systems biology. FEMS Yeast Res. 18, foy040 (2018).
Venditti, P., Di Stefano, L. & Di Meo, S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion 13, 71–82 (2013).
doi: 10.1016/j.mito.2013.01.008
Angelova, P. R. & Abramov, A. Y. Functional role of mitochondrial reactive oxygen species in physiology. Free Radic. Biol. Med . 100, 81–85 (2016).
doi: 10.1016/j.freeradbiomed.2016.06.005
Idelchik, M., Begley, U., Begley, T. J. & Melendez, J. A. Mitochondrial ROS control of cancer. Semin Cancer Biol. 47, 57–66 (2017).
doi: 10.1016/j.semcancer.2017.04.005
Kim, H. K. et al. Current and upcoming mitochondrial targets for cancer therapy. Semin Cancer Biol. 47, 154–167 (2017).
doi: 10.1016/j.semcancer.2017.06.006
Badrinath, N. & Yoo, S. Y. Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy. Carcinogenesis 39, 1419–1430 (2018).
doi: 10.1093/carcin/bgy148
Zong, W. X., Rabinowitz, J. D. & White, E. Mitochondria and cancer. Mol. Cell 61, 667–676 (2016).
doi: 10.1016/j.molcel.2016.02.011
Kim, S. J. et al. CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane. Cell Metab. 16, 274–283 (2012).
doi: 10.1016/j.cmet.2012.06.012
Chandrashekar, D. S. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649–658 (2017).
doi: 10.1016/j.neo.2017.05.002
Li, L. & Li, W. Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol. Ther. 150, 33–46 (2015).
doi: 10.1016/j.pharmthera.2015.01.004
Koc, E. C. et al. Identification and characterization of CHCHD1, AURKAIP1, and CRIF1 as new members of the mammalian mitochondrial ribosome. Front Physiol. 4, 183 (2013).
doi: 10.3389/fphys.2013.00183
Nagar, H. et al. CRIF1 deficiency induces p66shc-mediated oxidative stress and endothelial activation. PLoS One 9, e98670 (2014).
doi: 10.1371/journal.pone.0098670
Piao, S. et al. CR6 interacting factor 1 deficiency promotes endothelial inflammation by SIRT1 downregulation. PLoS One 13, e0192693 (2018).
doi: 10.1371/journal.pone.0192693
Moloney, J. N. & Cotter, T. G. ROS signalling in the biology of cancer. Semin Cell Dev. Biol. 80, 50–64 (2018).
doi: 10.1016/j.semcdb.2017.05.023
Ismail, N. A. et al. Antioxidant enzyme activities in hepatic tissue from children with chronic cholestatic liver disease. Saudi J. Gastroenterol. 16, 90–94 (2010).
doi: 10.4103/1319-3767.61234
Prete, C. D. et al. Effect of superoxide dismutase, catalase, and glutathione peroxidase supplementation in the extender on chilled semen of fertile and hypofertile dogs. J. Vet. Sci. 19, 667–675 (2018).
doi: 10.4142/jvs.2018.19.5.667
Tokar, T. et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res 46(D1), D360–D370 (2018).
doi: 10.1093/nar/gkx1144
Ran, Q. et al. CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells. PLoS One 9, e85328 (2014).
doi: 10.1371/journal.pone.0085328
Feng, L., Cheng, K., Zang, R., Wang, Q., Wang, J. miR-497-5p inhibits gastric cancer cell proliferation and growth through targeting PDK3. Biosci. Rep. 39, BSR20190654 (2019).
Hong, S., Yan, Z., Wang, H., Ding, L., Bi, M. Up-regulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3. Biosci. Rep. 39, BSR20191123 (2019).
Huang, X., Wang, L., Liu, W. & Li, F. MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2. Oncol. Lett. 17, 3425–3431 (2019).
pubmed: 30867780
pmcid: 6396182
Chai, L. et al. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. Cancer Manag. Res. 10, 989–1003 (2018).
doi: 10.2147/CMAR.S163335
Xu, G. S., et al. MiR-497-5p inhibits cell proliferation and metastasis in hepatocellular carcinoma by targeting insulin-like growth factor 1. Mol. Genet Genomic Med. 7, e860 (2019).
Clement, M. V., Hirpara, J. L. & Pervaiz, S. Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ. 10, 1273–1285 (2003).
doi: 10.1038/sj.cdd.4401302
Chen, Z. X. & Pervaiz, S. Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ. 14, 1617–1627 (2007).
doi: 10.1038/sj.cdd.4402165
Chen, Z. X. & Pervaiz, S. Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ. 17, 408–420 (2010).
doi: 10.1038/cdd.2009.132
Low, I. C., Loh, T., Huang, Y., Virshup, D. M. & Pervaiz, S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56delta stabilizes its antiapoptotic activity. Blood 124, 2223–2234 (2014).
doi: 10.1182/blood-2014-03-563296